Alzheimer’s Association Commends United Kingdom’s Approval of Leqembi, But Condemns Decision to Deny NHS Access

CHICAGO, Aug. 22, 2024 /PRNewswire/ — The Alzheimer’s Association welcomes today’s decision by the United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) to approve Leqembi® (lecanemab) for the treatment of Alzheimer’s disease. However, while celebrating this…

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.